Tecentriq takes lead in China for extensive-stage small cell lung cancer

14 February 2020
tecentriq_big

Continuing its progress in addressing different cancer types across different geographies, immuno-oncology blockbuster Tecentriq (atezolizumab) has secured Chinese approval in extensive-stage small cell lung cancer (ES-SCLC).

Last year, Roche (ROG: SIX) became the first company to offer an immuno-oncology option for people with this kind of cancer, when it  won approval in Europe and in the USA, ahead of rival options from AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK).

Approval in China will help the Swiss cancer giant entrench its lead, with Tecentriq taking in 1.88 billion Swiss francs ($1.9 billion) in 2019, up 143% from the year before. In the fourth quarter revenues were 248 million Swiss francs, up 136% from the like period of 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology